IGM Biosciences (IGMS)
(Delayed Data from NSDQ)
$8.88 USD
+0.05 (0.57%)
Updated Aug 13, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IGMS 8.88 +0.05(0.57%)
Will IGMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IGMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IGMS
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
IGMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Other News for IGMS
IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences GAAP EPS of -$0.79, revenue of $1.26M
IGM Biosciences Inc (IGMS) Q2 2024 Earnings: EPS of -$0.79, Revenue of $1.3 Million
IGM Biosciences reports Q2 EPS (79c), consensus (4c)
Notable Two Hundred Day Moving Average Cross - IGMS